Skip to main content
Top
Published in: International Journal of Clinical Pharmacy 5/2017

01-10-2017 | Short Research Report

Design and application of a medication assessment tool for secondary prevention of stroke

Authors: Marise Gauci, Francesca Wirth, Liberato Camilleri, Lilian M. Azzopardi, Anthony Serracino-Inglott

Published in: International Journal of Clinical Pharmacy | Issue 5/2017

Login to get access

Abstract

Background Optimisation of drug therapy is essential in the care of older persons and may be facilitated by application of medication assessment tools (MATs). Objective To design, psychometrically evaluate and apply an innovative MAT for secondary prevention of ischaemic stroke with particular relevance to older persons. Method Review criteria were selected from clinical practice guidelines and MAT-CVA was developed, validated and tested for reliability and feasibility. MAT-CVA was applied to 150 patients with a diagnosis of ischaemic stroke or transient ischaemic attack admitted to a rehabilitation hospital. Results MAT-CVA consists of 17 criteria sectioned into antithrombotic, lipid lowering, antihypertensive and glycaemic therapy. Content validity was demonstrated for all criteria. Reliability was confirmed with kappa values of 0.80 for both inter- and intraobserver agreements. Mean application time for the two observers was 5.55 and 6.56 min. Adherence to applicable criteria was 55% and justified non-adherence was 22.3%. Non-adherence was predominantly evident for prescription of anticoagulation in concurrent atrial fibrillation (36.4%), thiazide diuretics ± angiotensin converting enzyme inhibitors for hypertension (26.8%) and dipyridamole at the recommended dose (24.0%). Conclusion Application of MAT-CVA indicated good overall adherence and identified gaps in clinical performance which may be targeted to enhance drug therapy optimisation.
Appendix
Available only for authorised users
Literature
1.
go back to reference Page RL, Linnebur SA, Bryant LL, Ruscin JM. Inappropriate prescribing in the hospitalized elderly patient: defining the problem, evaluation tools, and possible solutions. Clin Interv Aging. 2010;5:75–87.CrossRefPubMedPubMedCentral Page RL, Linnebur SA, Bryant LL, Ruscin JM. Inappropriate prescribing in the hospitalized elderly patient: defining the problem, evaluation tools, and possible solutions. Clin Interv Aging. 2010;5:75–87.CrossRefPubMedPubMedCentral
2.
go back to reference Zulman DM, Asch SM, Martins SB, Kerr EA, Hoffman BB, Goldstein MK. Quality of care for patients with multiple chronic conditions: the role of comorbidity interrelatedness. J Gen Intern Med. 2013;29(3):529–37.CrossRefPubMedPubMedCentral Zulman DM, Asch SM, Martins SB, Kerr EA, Hoffman BB, Goldstein MK. Quality of care for patients with multiple chronic conditions: the role of comorbidity interrelatedness. J Gen Intern Med. 2013;29(3):529–37.CrossRefPubMedPubMedCentral
3.
go back to reference McAnaw JJ, Hudson S, McGlynn S. Development of an evidence-based medication assessment tool to demonstrate the quality of drug therapy use in patients with heart failure. Pharm World Sci. 2003;11(Suppl):R17. McAnaw JJ, Hudson S, McGlynn S. Development of an evidence-based medication assessment tool to demonstrate the quality of drug therapy use in patients with heart failure. Pharm World Sci. 2003;11(Suppl):R17.
4.
go back to reference Liu H, Chen H, Johnson J, Lin Y. A medication assessment tool to evaluate adherence to medication guideline in asthmatic children. Int J Clin Pharm. 2013;35(2):289–95.CrossRefPubMed Liu H, Chen H, Johnson J, Lin Y. A medication assessment tool to evaluate adherence to medication guideline in asthmatic children. Int J Clin Pharm. 2013;35(2):289–95.CrossRefPubMed
5.
go back to reference Garcia BH, Smabrekke L, Trovik T, Giverhaug T. Application of the MAT-CHDSP to assess guideline adherence and therapy goal achievement in secondary prevention of coronary heart disease after percutaneous coronary intervention. Eur J Clin Pharmacol. 2013;69(3):703–9.CrossRefPubMed Garcia BH, Smabrekke L, Trovik T, Giverhaug T. Application of the MAT-CHDSP to assess guideline adherence and therapy goal achievement in secondary prevention of coronary heart disease after percutaneous coronary intervention. Eur J Clin Pharmacol. 2013;69(3):703–9.CrossRefPubMed
6.
go back to reference Hogli JU, Smabrekke L, Garcia BH. MAT-CAP: a novel medication assessment tool to explore adherence to clinical practice guidelines in community-acquired pneumonia. Pharmacoepidemiol Drug Saf. 2014;23(9):933–41.CrossRefPubMed Hogli JU, Smabrekke L, Garcia BH. MAT-CAP: a novel medication assessment tool to explore adherence to clinical practice guidelines in community-acquired pneumonia. Pharmacoepidemiol Drug Saf. 2014;23(9):933–41.CrossRefPubMed
7.
go back to reference Grech L, Ferrito V, Serracino Inglott A, Azzopardi LM. Development and validation of RhMAT, as medication assessment tool specifically designed for rheumatoid arthritis management. JPHSR. 2016;7(1):89–92. Grech L, Ferrito V, Serracino Inglott A, Azzopardi LM. Development and validation of RhMAT, as medication assessment tool specifically designed for rheumatoid arthritis management. JPHSR. 2016;7(1):89–92.
8.
go back to reference Kernan WN, Ovbiagele B, Black HR, Bravata DM, Chimowitz MI, Ezekowitz MD, et al. Guidelines for the prevention of stroke in patients with stroke or transient ischaemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014;45(7):2160–236.CrossRefPubMed Kernan WN, Ovbiagele B, Black HR, Bravata DM, Chimowitz MI, Ezekowitz MD, et al. Guidelines for the prevention of stroke in patients with stroke or transient ischaemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014;45(7):2160–236.CrossRefPubMed
Metadata
Title
Design and application of a medication assessment tool for secondary prevention of stroke
Authors
Marise Gauci
Francesca Wirth
Liberato Camilleri
Lilian M. Azzopardi
Anthony Serracino-Inglott
Publication date
01-10-2017
Publisher
Springer International Publishing
Published in
International Journal of Clinical Pharmacy / Issue 5/2017
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-017-0515-6

Other articles of this Issue 5/2017

International Journal of Clinical Pharmacy 5/2017 Go to the issue